Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02771197
Title Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Northside Hospital, Inc.
Indications

acute myeloid leukemia

Therapies

Fludarabine + Melphalan

Pembrolizumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.